About DRG Epidemiology

DRG’s Epidemiology provides bottom-up, patient-level forecasts, detailing disease trends from 10- to 20-year outlook periods to help you validate investments and identify growth opportunities in your markets of interest.

All of our epidemiological data, methods and insight are distributed via DRG’s Insights Platform, allowing the user to easily navigate between world regions and patient populations, as well as download epidemiological forecast data into an MS Excel format for offline use.

All epidemiological forecasts may be supplemented with custom deliverables, such as:

  • Chart reviews or more granular stratification using DRG’s in-house real world datasets or physician survey data
  • Customized and interactive patient flow models or additional subpopulations or metrics
  • Expanded geographical coverage or extended forecast periods beyond those available

Coverage

Our robust patient population sizing data includes therapeutic coverage of 140+ indications and 3400+ patient subpopulations, including extensive oncology subpopulation data by stage, line of therapy, and biomarker, as well as continually expanding niche and rare disease coverage.

The geographic breadth of data includes mature market (G7) reporting for all 140+ indications, as well as 90% global population coverage for the high-profile diseases, and expanded penetration for emerging and rest-of-world markets in select indications.

Methods

For over 20 years, our data and methodology have been developed and refined by DRG’s Epidemiology team of industry-leading subject matter experts, driven by rigorous methodology to uncover the impact of exposure, risk, and treatment, in addition to historical trends and age and gender cohorts.

All of our epidemiological forecasts are accompanied by a transparent description of our methods and data sources, the details of our systematic review underlying each forecast and associated summary evidence tables, and access to the authoring epidemiologist.

Table of contents

  • Mature Markets Data
    • Introduction
      • Key Findings
      • Overview
        • Event Rate of Hospitalized Clostridium Difficile Infection per 1,000 People of All Ages in 2016 and 2026
        • Relative Sizes of the Contributing Factors to the Trend in Hospitalized Events of Clostridium Difficile Infection over Ten-Year Forecast Period
        • Analysis of Diagnosed Events of Clostridium Difficile Infection in the Countries Under Study, by Stage: 2016
    • Epidemiology Data
    • Methods
      • Diagnosed Events: Hospitalized
      • Diagnosed Hospitalized Events: Recurrent
      • Diagnosed Hospitalized CDI Events Transferred from Nursing Home
      • Drug-Treated Hospitalized Events
      • Severity - Based on Literature Data with Strict Application of Criteria
      • Severity- Based on Physician Survey
      • Comorbidities
      • Diagnosed Healthcare-Associated Events
      • Diagnosed Healthcare-Associated Events: Recurrent
      • Diagnosed Community-Associated Events
      • Diagnosed CDI Events
    • Reference Materials
      • Literature Review
      • Risk/Protective Factors
      • Bibliography

Author(s): Devashri Mukherjee, MPH; Lade Ayodele

Research enthusiast with a flair for academic writing, member of the DRG family since April 2015 and working from the India office. Started off career with a bachelor’s in Dental Surgery followed by a master’s in Public health; having primarily worked in the hospital setting as a Research Consultant prior to DRG and with 10 international publications to my credit.

Dr. Ayodele has expertise in forecasting disease populations and is an epidemiology expert in chronic diseases including cancers and cardiovascular diseases, in both the major and emerging pharmaceutical markets. Prior to joining Decision Resources Group, she researched antiretroviral therapy funding, availability and access at the Clinton Foundation Center for Strategic HIV Operations Research. More recently, she was a Medical Innovation and Leadership fellow at Blue Cross Blue Shield of Massachusetts, where she researched and developed strategic plans on health care utilization and quality improvement. Dr. Ayodele holds a Master in Public Health degree (quantitative methods concentration) from Harvard and a medical degree from the University of Ibadan in Nigeria. She is currently pursuing a in epidemiology at Boston University School of Public Health with a focus in pharmacoepidemiology.